688293 Shanghai OPM Biosciences
- 36.09
- -1.62-4.30%
Shanghai OPM Biosciences News
Oppo Mai (688293): Strong growth in the first quarter of 2024 culture media contributed significantly to overseas revenue
Announcement: Optomax released its 2023 Annual Report and 2024 Quarterly Report. In 2023, the company's revenue was 243 million yuan, a year-on-year decrease of about 17.41%. Net profit attributable to mother was 54.0385 million yuan, a year-on-year decrease of 48
Opmax (688293.SH): Purchased 0.92% of shares at a cumulative cost of 46.6059 million yuan
Gelonghui (688293.SH) announced on May 31, 2024, that as of May 31, 2024, the company had repurchased 1,056,703 shares of the company through centralized bidding transactions, accounting for 0.9207% of the company's current total share capital of 114,772,460 shares. The highest transaction price was 58.00 yuan/share, the minimum transaction price was 29.88 yuan/share, and the total transaction amount was 46,605,916.14 yuan (not including transaction fees such as trading commissions).
Oppo Mai (688293): Rapid growth in 24Q1 medium revenue
Incident: The company released the 2023 report & 2024 quarterly report. In 2023, it achieved revenue of 243 million yuan (-17.4%), net profit of 54 million yuan (-48.7%), and deducted non-net profit of 34.72 million (-
OPM Biosciences' Shareholder to Cut Stake
Shenzhen Dachen Chuanglian Equity Investment Fund Partnership (Limited Partnership) plans to reduce its holdings in Shanghai OPM Biosciences (SHA:688293), the company said in a Thursday filing on the
Oppo Mai (688293): The medium business has entered a period of rapid growth
Matters: Opomax publishes its 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved revenue of 243 million yuan, a year-on-year decrease of 17.4%, and net profit to mother of 54 million yuan, a year-on-year decrease of 48.7%.
Oppo Mai (688293): The medium business showed upward growth, and international expansion contributed to the company's performance growth
Incident Overview (1) Company Announcement 2023 Annual Report: 23 Achieved operating income of 243 million yuan for the full year, a year-on-year decrease of 17.41%, and realized net profit to mother of 54 million yuan, a year-on-year decrease of 48.72%, and realized a year-on-year decrease of 48.72%.
Express News | Oppo Mai: Dachen Chuanglian plans to reduce its shareholding by no more than 1.74%
Oppo Mai (688293): Sales revenue from the improved medium business increased significantly in the first quarter compared to the previous quarter
Core view Opmax's revenue for the full year of 2023 was 243 million yuan, a year-on-year decrease of 17.41%, mainly due to certain obstacles to the financing process of some biotech in '22, which led to a significant drop in CDMO revenue compared to last year
Opmax (688293.SH): Has repurchased a total of 0.9207% of the company's shares
Gelonghui (688293.SH) announced on May 6, 2024, that as of April 30, 2024, the company had repurchased 1,056,703 shares of the company through centralized bidding transactions, accounting for 0.9207% of the company's current total share capital of 114,772,460 shares. The highest transaction price was 58.00 yuan/share, the minimum transaction price was 29.88 yuan/share, and the total transaction amount was 46,605,916.14 yuan (not including transaction fees such as trading commissions).
Express News | Opmax: Huajie Investment plans to reduce its shareholding by no more than 1.9% through bulk transactions
Oppo Mai (688293) 2023 Report & 2024 Quarterly Report Review: Excellent Growth Rate of Medium Performance, Continuous Verification of Volume Logic
Key investment events: On April 29, 2024, the company released the 2023 Annual Report & 2024 Quarterly Report. The company's revenue in 2023 was 243 million yuan (-17.4%, year-on-year in parentheses, same below)
Oppo Mai (688293): Overseas market expansion of the medium business achieved results
Performance was under pressure in the short term, and overseas market expansion achieved results. In 2023, the company achieved revenue of 243 million yuan (-17.4% year over year), excluding major IVD enterprise customers and a major overseas customer in the same period last year due to special reasons
Oppo Mai (688293): 2023 results are in line with expectations, optimistic about subsequent performance
Note: The company announced 2023 and 24Q1 results. In 2023, the company achieved revenue of 243 million yuan (yoy -17.4%); realized net profit of 54.04 million yuan (yoy -48.7%); achieved return to mother
Oppo Mai (688293) Company Information Update Report: Rapid Growth in Media Business, CDMO Reforms Before Starting
The 2023 performance was under pressure in the short term, and the medium business led to a rapid recovery in 2024Q1. The company achieved operating income of 243 million yuan in 2023, a year-on-year decrease of 17.41%; net profit to mother was 54 million yuan, the same
Oppo Mai (688293.SH): Proposed integration of CDMO business
On April 28, Gelonghui (688293.SH) announced that the company plans to integrate the CDMO business, increase the capital of its wholly-owned subsidiary Shanghai Silun Biotechnology Co., Ltd. (“Silun Biotech”), and transfer assets related to the CDMO business belonging to the company and its wholly-owned subsidiary Shanghai Opumai Biotechnology Co., Ltd. to Silun Biotech to fully utilize the “Silun Biotech” brand effect and enhance the competitiveness of the company's CDMO business. After the capital increase is completed, Silun Biotech is still a wholly-owned subsidiary of Opmax. This asset transfer will not cause changes in the scope of the company's consolidated statements and is not involved
Oppo Mai (688293.SH) reported 2023 annual results, with net profit of 54.085 million yuan, a year-on-year decrease of 48.72%
According to the Zhitong Finance App, Oppo Mai (688293.SH) released its 2023 annual report, with revenue of 243 million yuan, a year-on-year decrease of 17.41%. Net profit attributable to shareholders of listed companies was 54.085 million yuan, a year-on-year decrease of 48.72%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 347.24,900, a year-on-year decrease of 60.89%. Basic earnings per share were $0.47. A cash dividend of RMB 2.30 (tax included) is distributed to all shareholders for every 10 shares.
Express News | A-share review: the three major indices collectively adjusted the turnover of the two markets exceeded trillion dollars for five consecutive trading days
Oppo Mai (688293.SH): Dachen Chuanglian reduced its holdings by a total of 1.7428%
On March 15, Ge Longhui (688293.SH) announced that it received a “Notice Letter on Simple Equity Changes for Shareholders Holding 5% or More” from Shenzhen Dachen Chuanglian Equity Investment Fund Partnership (Limited Partnership) (“Dachen Chuanglian”), a shareholder holding 5% or more of the company's shares. Dachen Chuanglian reduced the company's holdings of 2,000 shares and 300 shares through bulk transactions between October 17, 2023 and March 14, 2024, accounting for 1.7428% of the company's total share capital. After this change in equity, Dachen Chuanglian held 5,738,563 shares of the company's shares.
Xiao Zhihua, the controlling shareholder of Opmax (688293.SH), and director Ni Liangping increased their holdings by a total of 79,900 shares
Oppo Mai (688293.SH) announced that Xiao Zhihua, the controlling shareholder, chairman and general manager of the company, as well as directors and directors...
Oppo Mai (688293): Medium and CDMO two-wheel drive to go out to sea to open up a wide space
The first domestic medium, the medium and CDMO two-wheel drive. Established in 2013, Opmax is a high-tech enterprise specializing in cell culture products and services. The company landed on the Science and Technology Innovation Board in 2022, making it the first in China
Analysis
Price Target
No Data
